Ventyx Biosciences’ (VTYX) Equal Weight Rating Reiterated at Wells Fargo & Company

Wells Fargo & Company reissued their equal weight rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock.

A number of other analysts also recently commented on the stock. Canaccord Genuity Group downgraded shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $16.00 to $14.00 in a research report on Thursday. Oppenheimer cut Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday. Lifesci Capital restated a “market perform” rating and issued a $14.00 target price on shares of Ventyx Biosciences in a research report on Thursday. UBS Group reiterated a “neutral” rating and set a $14.00 price target (down from $20.00) on shares of Ventyx Biosciences in a research report on Thursday. Finally, HC Wainwright downgraded Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 price objective on the stock. in a research note on Thursday. Eight research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $14.86.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX opened at $13.81 on Thursday. The stock has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23. Ventyx Biosciences has a 1 year low of $0.78 and a 1 year high of $25.00. The business has a fifty day moving average of $9.27 and a 200-day moving average of $5.30.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. On average, equities research analysts predict that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Buying and Selling at Ventyx Biosciences

In other news, CEO Raju Mohan sold 47,345 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Nuss sold 12,675 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider directly owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 14.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Ventyx Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of VTYX. Affinity Asset Advisors LLC purchased a new stake in shares of Ventyx Biosciences in the second quarter valued at $9,707,000. Marshall Wace LLP purchased a new stake in Ventyx Biosciences in the 2nd quarter worth about $5,129,000. Baker BROS. Advisors LP acquired a new stake in Ventyx Biosciences during the 3rd quarter worth about $3,182,000. AQR Capital Management LLC boosted its position in Ventyx Biosciences by 925.6% during the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock worth $1,012,000 after acquiring an additional 794,401 shares during the period. Finally, Vanguard Group Inc. grew its stake in Ventyx Biosciences by 19.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock valued at $11,725,000 after acquiring an additional 607,725 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences News Summary

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.